Pluristem Therapeutics Inc. is announcing that its subsidiary, Pluristem Ltd., has been awarded $3.3 million Israel Innovation Authority of the Israeli Ministry of Economy & Industry. The grant will support clinical trials as well as research and development activities for calendar year 2016.
“We are delighted to receive the Israeli Innovation Authority Grant this year, ” stated Zami Aberman, chairman and CEO in the May 9, 2016 news release. “The continued backing of the Israeli Innovation Authority is a vote of confidence in Pluristem technology and strategy and support the execution of our plans.”
Karine Kleinhaus, M.D., M.P.H. is divisional vice president, North America for Pluristem. She told OTW, “Typically, it covers all of our activity (excluding G&A). We submit a grant request with the planned activities for the year, the Israel Innovation Authority of the Israeli Ministry of Economy & Industry makes an assessment of the grant request and approves the specific activities, which typically are in our entire field of operations: research, development, manufacturing, manufacturing scale up, quality, clinical trials, pre-clinical trials, regulation, etc.”
